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Abstract
Background and aims: Steroid-resistance presents a management challenge in ulcerative colitis.
How steroid-resistance occurs is unknown, but cytomegalovirus infection, often unrecognised, may
be the cause in some patients. Current evidence and therapeutic recommendations are examined.
Methods: A systematic review of PubMed and EMBASE databases was performed. Search and
exclusion criteria are defined in the text.
Results: Heterogeneity of experimental design and definitions of key terms were notable.
Criteria for cytomegalovirus disease, infection or detection varied, as did definitions of steroid-
resistance. CMV infection defined by antigenaemia or serology was common in patients on
steroids and associated with a higher rate of steroid-resistance (41.66–61% versus 0–68% in
steroid-responsive patients). Colonic mucosal cytomegalovirus disease detected by histopathol-
ogy was associated with intravenous steroid-resistance in 5–36%, compared to 0–10% of steroid-
responsive patients. CMV colitis has rarely been reported in association with ulcerative colitis
without steroids or other immunomodulators. CMV colitis in healthy individuals is so exceptional
as to be the topic of case reports.
Conclusion: Ulcerative colitis and its treatment put patients at risk of CMV infection or
reactivation. A distinction is necessary between CMV disease (colitis) and CMV infection. Only
colonic mucosal CMV infection detected by histopathology appears clinically relevant and
appropriate for antiviral therapy. CMV antigenaemia may be associated with steroid-resistance,
but may also be a self-limiting marker of viral reactivation. The impact of CMV on steroid-
resistance is complicated by inconsistencies in the literature. Coherent definitions of clinically
relevant CMV infection and steroid-resistance are needed.
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Ulcerative colitis (UC) is a relapsing-remitting condition.
During an acute relapse, the mainstay of treatment is
corticosteroid therapy.1 Although highly effective for many
patients, a proportion of patients do not respond.2 The
reasons are unclear, but reports suggest that cytomegalovirus
(CMV) may often be overlooked. The prevalence of CMV
infection appears to be particularly high in steroid-resistant
colitis, raising the question of whether CMV is cause or
consequence of a relapse or therapeutic refractoriness. 36%
of an Italian cohort of steroid-resistant Crohn's disease andUC
patients with acute severe colitis were found to be CMV
positive by immunohistopathology and buffy coat PCR. The
authors concluded that CMV is a frequent cause of refractory
colitis.3 A Japanese study detected CMV using immunohisto-
lopathology in 21% of colectomy specimens, all of which
(almost by definition) were steroid-resistant.4 An American
group found that 25% of a small number (n=40) of patients
with refractory UC were CMV positive using immunohisto-
chemistry, compared to 2.5% of 40 patients with treatment-
responsive colitis (p=0.007).5 These data suggest that CMV
may be associated with or cause about a third of cases of
refractory colitis, but this is much higher than is recognised in
clinical practice, which in turn raises a number of questions.
How robust is this evidence? How should CMV “infection”
be defined in this clinical context? What, then, is the role of
antiviral therapy? Should all UC patients have CMV assess-
ment before therapy? How is steroid-refractoriness defined?
This article reviews the literature, discusses experimental
design and proposes some answers that need to be confirmed
by appropriate trials.2. Methods
A systematic review of PubMed and EMBASE databases was
performed, using the terms inflammatory bowel disease;
colitis, ulcerative, Crohn's disease, drug resistance, cytomega-
lovirus infection, cytomegalovirus, CMV, requiring colectomy,
steroid resistant, steroid refractory, treatment refractory andtreatment resistant. Free text and Medical Subject Heading
(Mesh) strategies were deployed. Exclusion criteria were:
studies not published in the English language; those inacces-
sible to Oxford University e-resources; those unrelated to
humans or irrelevant to the topic; and case reports/case series.
The PubMed search revealed 45 papers, of which 35 were
then excluded for irrelevance or unavailability. The 10
remaining ranged in level of evidence from prevalence
studies to cohort or case-control studies. A similar search of
EMBASE produced 63 papers. After exclusions, all but one
paper overlapped with those found on PubMed. There were
no randomised controlled trials or systematic reviews in the
Cochrane database.
3. Analysis
3.1. What does CMV infection mean?
Although the population seroprevalence of CMV is high,
including in developing countries,6 primary infection in
healthy individuals is usually asymptomatic.7 The virus exists
in a latent state thereafter.7 However, reactivation is
common. Immunocompromised patients are known to be
more susceptible to reactivation of latent CMV,8,9 which can
then present as a variety of clinical syndromes or diseases.10
Prior to the development of highly active anti-retroviral
therapy, 21–44% of acquired immunodeficiency syndrome
(AIDS) patients suffered CMV-related disease including
retinitis, encephalitis, polyradiculopathy and mononeuri-
tis.11 Bonemarrow transplant recipients are also at increased
risk, with CMV infection having wide-ranging detrimental
effects, including graft rejection.12
A distinction must therefore be made between CMV
infection, where a person is CMV-positive on polymerase
chain reaction (PCR) or serological testing, and CMV disease,
where clinical symptoms are manifest.13,14 In the current
context, the term disease refers to CMV colitis, causing
bloody diarrhoea, abdominal cramps, or fever that might
otherwise be attributed to UC. It is this that is considered a
possible cause of steroid-resistance. The distinction is
usually achieved by light microscopy of rectal or colonic
Figure 1 Algorithm for diagnosis, treatment and assessment
of response to treatment of clinically relevant1 CMV colitis.
1 Clinically relevant in this context means colitis that deteriorates
or persists despite corticosteroid therapy.
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cation tests generally identify patients with coexistent
rather than causative infection. This distinction has an
impact on the detection and implied causation of CMV in the
severity of relapse in ulcerative or steroid-resistance.
3.2. How is CMV best detected?
3.2.1. Serology
IgG antibodies reflect exposure and given that up to 70% of
the population is seropositive,15 a positive result is unin-
formative.5 Conversely, about 30% of inflammatory bowel
disease patients will therefore not be at risk of CMV
reactivation since they will not have had previous infection.
IgG serology is a fast way of identifying this sub-group and
excluding CMV reactivation from the differential diagnosis.
IgM antibodies, on the other hand, indicate recent infec-
tion,14,16 but are not specific to colonic disease.17 CMV
antigenaemia assays, which involve staining for CMV in
peripheral blood leucocytes, are open to subjective inter-
pretation13 and assays can be positive without gastrointest-
inal involvement.18 Antigenaemia assays have largely been
replaced by CMV detection and quantification through
molecular techniques such as PCR.
3.2.2. Histopathology
Histopathological examination of colorectal mucosal biop-
sies, stained with haematoxylin and eosin (H&E), appears to
be a reliable method of detecting colonic mucosal CMV
disease (colitis) that is clinically relevant13 (Fig. 1)(Table 1).
Clinical relevance in this context means colitis that
deteriorates or persists despite oral corticosteroids.19 CMV
inclusion bodies are found in greatest number around
mucosal blood vessels or at the base of ulcers, so superficial
mucosal biopsies may not always be accurate.20,21 Never-
theless, in most clinically relevant CMV disease in UC, the
CMV inclusions are numerous and easily seen on H&E stained
mucosal biopsies.22 Some studies have used colectomy
specimens, but whilst specific, is clearly only applicable in
retrospect.
Standard H&E staining has been reported to be 92–100%
specific, but often insensitive (10–87%).23 The pivotal
question about sensitivity is the reference technique for
CMV infection and CMV disease (colitis) used by the
investigators, since many infections have little clinical
relevance with a virus that is so highly prevalent. Immuno-
histochemistry (IHC) has been found to be more sensitive
than H&E staining (78–93%),23 but is generally used only to
confirm findings by conventional light microscopy unless the
specific question of CMV colitis has been raised by the
clinician.
3.2.3. PCR
Molecular diagnostic techniques such as real-time PCR are
used to detect and quantify CMV viraemia. They are sensitive,
but not specific for clinically relevant CMV colitis. In one
study, 24 patients with UC due to undergo colectomy for
refractoriness to medical treatment (corticosteroids and in
some cases ciclosporin or infliximab) were compared with
patients undergoing colonic resection for colorectal cancer.24
Although CMV was detected by PCR in 13% and by histopathol-ogy in 4% of UC cases, comparedwith none of the controls, the
difference between cases and controls was not significant.
The low CMV detection rate is notable in a patient population
that was highly immunocompromised, but the numbers are
too small to draw definitive conclusions. Furthermore, the
clinical relevance remains unclear, because it is not shown
that treatment for CMV would have altered the outcome of
colectomy.
In transplant medicine, studies have shown that although
positive antigenaemia and PCR results may not by themselves
constitute CMV disease, a quantitative cut-off point in the
levels of each can help identify patients at risk of going on to
develop CMV disease.25 There are at present no data with
respect to inflammatory bowel disease.
In contrast, a Japanese study reported that PCR detected
CMV in the inflamed mucosa of 17 (57%) of thirty patients
with ulcerative colitis refractory to immunomodulators and
in none of four treatment-responsive patients.26 The
disparity in numbers suggests that patient-selection in this
study was highly biased, since the response to immunomo-
dulators is generally estimated to be around 70%.1 Further-
more, histopathological analysis with H&E and IHC in this
Table 1 Summary of the prevalence of colonic CMV disease in steroid-resistant, steroid-responsive and non-steroid groups.
Study Method of CMV detection Overall (%) Steroid-refractory (%) Steroid-responsive (%) Other (%)
Cottone
20013
H&E a and IHC b – 36 (7/19) – –
Kambham
20045
IHC – 25 (10/40) 2.5 (1/40) –
H&E – 5 (2/40) 0 –
Criscuoli
200433
IHC 17 (7/42) 33 (4/12) 10 (3/30) –
Takahashi
20044
H&E 10 (9/94)
Maconi
200528
H&E – 27 (15/55) 9.1 (2/22) –
Kojima
200631
H&E – 1.3 (1/72) N/A 16 (5/32, severe colitis)
IHC – 8.3 (6/72) N/A 25 (8/32, severe colitis)
Domènech
200832
H&E and/or IHC – 32 (6/19) 0 0 (inactive UC and healthy
controls)
a H&E: Haematoxylin and eosin staining of colonic mucosal biopsies.
b IHC: Immunohistochemistry of colonic mucosal biopsies.
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positive with PCR. The authors gave antiviral therapy to
those identified as CMV-positive by PCR and intensified
immunomodulator therapy in CMV-negative patients, report-
ing “a high remission rate”, but numbers are too small and
the lack of controls make it inappropriate to draw any
conclusions. In the Consensus on Opportunistic Infections,
ECCO guidelines recommend tissue (not serology) PCR or IHC
as the methods of choice for excluding CMV colitis.14 When
speed is essential, such as for patients with acute severe
colitis facing emergency colectomy, urgent H&E staining can
provide an answer faster than PCR or IHC, within 12 h.
3.3. CMV and steroid-resistance
It is conceivable that the association between CMV and
steroid-resistance is simply a marker of higher viral reactiva-
tion rates in immunocompromised patients and reflects
impaired cellular immunity caused by corticosteroids.27–29
Data suggesting an association between CMV and steroid-
resistance therefore need critical appraisal, since the
association may be artefactual.
To deal with retrospective studies first, CMVwas identified
by H&E and IHC-staining in 8/39 colectomy specimens, all
performed for steroid-resistant UC.4 Since 6/8 with CMV had
their colectomy for an acute severe attack, the authors
reasonably suggested that CMV could cause an acute
deterioration and should be considered in steroid-resistant
cases. Another group used IHC to classify the surgical
specimens of severe UC (n=22), moderately active UC
(n=12), Crohn's disease (n=12) and colorectal cancer
(n=31) according to CMV infection density.30 All specimens
with dense CMV infection (“CMV disease”) (5/5) were steroid-
resistant and those with scattered CMV infection (8/9) were
significantly more likely to be steroid-resistant than CMV-
negative specimens (2/8) (p=0.005). The median daily dose
of steroid was significantly higher in the CMV-dense group
than the CMV-negative group (p=0.008).In a well-designed study, Maconi examined surgical speci-
mens of 77 UC patients and their corresponding colonoscopy
biopsy specimens, taken up to 12 months before colectomy.28
H&E staining and IHCwere used to detect CMV. 55/77 patients
had steroid-refractory UC and these were compared with 6/
77 patients who underwent colectomy because of toxic
megacolon, 7/77 for dysplasia or cancer and 9/77 due to
inability to control symptoms in the absence of steroids.
Although the proportion of CMV-positive specimens in steroid-
refractory patients was higher than the non-refractory group,
the difference was not statistically significant (p=0.123).
When clinical characteristics of the patients were examined
in relation to CMV-positivity, only current, systemic use of
corticosteroids was significantly associated (p=0.03). The
authors conclude that these data support an association
between CMV and steroid-resistance, but interpret it as
a reflection on viral reactivation due to corticosteroid
therapy, rather than CMV being a causal factor. The time
between biopsy and colectomy, however, did not affect the
CMV detection rate. Thismeans that if their theory about CMV
reactivation through immunosuppression is correct, the CMV
rates should be higher at the time of the surgery, since
colectomy is the final therapeutic stage for patients
completely refractory to immunomodulators. This is consis-
tent with another cohort study, which found no association
between steroid therapy and CMV positivity.31
The question is better answered by a more recent
prospective study of steroid-responsive and -refractory
patients, which included groups with inactive UC on main-
tenance azathioprine or mesalazine therapy, as well as
healthy controls with a normal colonoscopy and no family
history of UC.32 CMVwas detectable by H&E, IHC and PCRonly
in the steroid-refractory group, in 32% of 19 patients. There
were, however, no differences in clinical characteristics
between the CMV-positive and CMV-negative steroid-refrac-
tory patients, although a higher proportion of the CMV-
positive patients underwent colectomy. Another Italian group
detected CMV in the biopsies of 4 of 12 (33%) steroid-resistant
145The role of CMV in steroid-resistant ulcerative colitis: A systematic reviewpatients admitted with acute severe colitis and only 3 out of
30 steroid responsive patients (10%), although again there
were no substantial clinical differences between patients
with and without infection.33
Consequently, the question of whether CMV causes
steroid-resistance needs to be seen in both a clinical context
and in relation to the definition of CMV infection. Immuno-
suppressed patients are known to be susceptible to CMV-
reactivation, but studies must distinguish between serologi-
cal reactivation of CMV (infection) and tissue damage
(“disease”, or colitis) caused by CMV. In addition, the
association of CMV with steroid use is more specific than
for “immunosuppressant” drugs in general. Infliximab may
not exacerbate CMV. When 11 patients with inflammatory
bowel disease before and after treatment with infliximab
were assessed, 9 were seropositive and CMV was detected in
colonic biopsies of 3 patients prior to treatment. After
treatment, there was no worsening of colonic disease and in
one patient colonic CMV became undetectable.34
Reactivation of CMV during immunosuppressive therapy is
usually a self-limiting phenomenon and screening for latent
CMV infection before starting an immunomodulator is
unlikely to be useful.14 In contrast, when there is an episode
of steroid-refractory acute severe colitis, the possibility of
superimposed CMV disease should be considered and treated
if possible. Cases of CMV colitis occurring prior to steroid
therapy in inflammatory bowel disease patients have
been reported, but are so rare as to be confined to case
reports.35,363.4. What is the role of antiviral therapy in CMV
colitis?
The risks and benefits of CMV anti-viral therapy need to be
considered before decisions are taken either to treat CMV
disease or infection, or as adjunctive treatment for steroid-
resistant colitis, or even as prophylaxis for patients starting
steroids who have positive CMV serology or CMV viraemia.
CMV anti-viral drugs have the potential for serious side-
effects, including bone marrow suppression, pulmonary and
neurological dysfunction, so robust evidence of benefit is
needed.
In a prospective study of CMV anti-viral therapy for
steroid-resistant, moderate–severe UC, patients with CMV
antigenaemia were treated with ganciclovir if oral predni-
solone was clinically ineffective after 1–2 weeks.37 A CMV
antigenaemia assay, by direct immunostaining of peripheral
blood buffy coat, was used to divide 47 patients into CMV-
positive (n=16) and CMV-negative (n=31) groups, but H&E
and IHC staining of colonic mucosal biopsies was also
performed. Steroid-resistance was more common in the
CMV-positive group (n=13/16 vs 9/31, p=0.001). CMV-
positive patients also had more severe colitis, whether
judged endoscopically or by histopathology (p=0.016 and
0.013 respectively). Of these CMV-positive patients, 12/16
were given ganciclovir, while 3/16 needed colectomy and
one improved on steroids. Of those given ganciclovir, 8/12
improved and became CMV-negative on the antigenaemia
assay. However, the remaining 4 patients also became CMV-
negative and did not improve, suggesting that resolution of
CMV antigenaemia is insufficient to bring about clinicalimprovement. These are very small numbers, so no conclu-
sion other than proof-of concept for the effect of ganciclovir
is possible. Placebo-controlled studies are needed.38
A separate study examined 19 steroid-resistant patients
with UC (n=16) or Crohn's colitis (n=3), also using a CMV
antigenaemia assay, as well as H&E with IHC staining for CMV
in rectal biopsies to separate CMV-positive or -negative
patients.3 Of these 19 steroid-resistant patients 7/19 (36%)
were CMV-positive both by antigenaemia assay and histo-
pathology. Steroid-resistant, CMV-negative patients (n=11
UC, 1 Crohn's) were started on ciclosporin, while CMV-
positive patients (n=5 UC, 2 Crohn's) were given antiviral
therapy (ganciclovir n=4, or foscarnet n=2). One patient
was not treated with ganciclovir because CMV was only later
detected in the surgical specimen. 5/6 of patients treated
with antiviral therapy went into remission and became CMV-
negative. The remaining patient underwent colectomy due
to lack of response to antiviral therapy. Of the remaining 12
(CMV-negative) patients, it is not stated how many came to
colectomy. The authors concluded that CMV is a frequent
cause of steroid-resistant colitis and recommended rectal
biopsy to look for CMV in these circumstances.
In a further prospective study, colonic CMV was detected
in 32% of 19 steroid-refractory patients with active UC.32 Two
of these patients underwent colectomy due to clinical
deterioration and the remaining four were treated with
ganciclovir and ciclosporin. All four patients cleared colonic
CMV after treatment, although clinical remission was
achieved in only three, with the remaining patient under-
going colectomy. Although consistent with a beneficial effect
of CMV anti-viral therapy in steroid-resistant colitis, small
numbers and lack of controls make it impossible to make
therapeutic recommendations. ECCO guidelines currently
recommend that CMV-antiviral therapy with cessation of
immunomodulators is appropriate for CMV colitis complicat-
ing UC, but that chemoprophylaxis before immunomodulator
therapy is not indicated.143.5. How is steroid-resistant colitis defined?
Steroid-resistance and -refractoriness are very variably
defined, which contributes to confusion24 (Table 2). European
guidelines on the management of UC define steroid-refractory
colitis as those patients who have active disease despite
prednisolone up to 0.75mg/Kg/day over a period of 4weeks,19
but needs qualification. This is because the definition is likely
to evolve as the threshold for using anti-TNF therapy changes
and other therapeutic options develop. Steroid-resistance,
however, is not defined in the ECCO guidelines, although
steroid-dependence is defined as patients who are either
unable to reduce steroids below the equivalent of predniso-
lone 10 mg/d within 3 months of starting steroids, without
recurrent activedisease,orwhohavea relapsewithin3months
of stopping steroids. In addition, the term “chronic active
disease” can refer to patients dependent on, refractory to or
intolerant of steroids, meaning its use as a clinical definition is
no longer recommended.19 More specifically, the definition of
steroid-resistance is dependent on the length of time in which
a clinical response is judged to have occurred. This will in turn
directly influence the timing of a CMV assay and alternative/
antiviral therapy initiated. Inconsistency in the definition of
Table 2 Definitions of steroid resistance used in studies of
CMV.
Study Definition
Cottone
(2001)3
Persistent symptoms after 5–10 days of high
dose parenteral steroids
Wada
(2003)37
Patients who showed no tendency to
improvement, even when prednisone was
administered at a daily dose of 30 mg or more
for at least 2 weeks
Kambham
(2004)5
Absence of response to systemic steroids
administered for a period of 2 or more weeks
Criscuoli
(2004)33
Persistent symptoms despite intravenous
methylprednisolone 1 mg/Kg/day for 5–
10 days
Maconi
(2005)28
Chronically active UC with poor response to
medium–high dose of steroids for more than
2 weeks, irrespective of the use of
immunosuppressive treatment or the need for
urgent or elective surgery
Kubawara
(2007)30
Patients showing no tendency towards
improvement even when prednisolone was
administered at a daily dose of 30 mg or more
for at least 2 weeks
Domènech
(2008)32
The absence of clinical improvement after a
course of 7–10 days of 1 mg/kg/day of
intravenous prednisolone
146 K. Ayre et al.steroid-resistance will in turn affect the reported prevalence
of CMV, because the virus may be more prevalent in cases
where steroid therapy is continued for longer.
3.6. Can steroid-resistance be explained by CMV
increasing the severity of the colitis?
CMV appears to have a particular tropism for inflamed
mucosa.29,39,40 If this indeed true, then higher tropism of
CMV would be expected in more severe cases,17 which in turn
could increase the severity30 and therefore increase steroid-
resistance. This would bias any investigation into the role of
CMV in steroid-resistance. Steroid-resistance, however, should
not be seen as synonymous with severe colitis, although the
terms have regrettably often been used interchangeably. It is
important to draw a distinction between biological severity
and colitis that is “severe” (or more serious) as a consequence
of resistance to treatment.
When the CMV detection rates in 40 steroid-refractory UC
and Crohn's disease patients were compared with 40 steroid-
responsive patients and 40 non-colitis controls, the rate was
significantly higher in the refractory group (25% vs 2.5%,
p=0.007, as detected by IHC).5 The refractory group was
more likely to have clinically severe disease (pb0.001), as
defined by the Truelove & Witts' criteria. When the
respective mucosal biopsies or colectomy specimens of
those groups were compared, those from the refractory
group were more likely to have mucosal erosion/ulceration
(60% vs 35%, p=0.006), crypt destruction (p=0.013), or
architectural distortion (p=0.0027), although the number of
sections with grade 2/3 inflammation (1=mild, 2=moderate,3=severe) did not differ significantly. There was, however,
no association between CMV density and the severity of
inflammation.
A different approach retrospectively compared the CMV
detection rate in colectomy specimens classified according to
surgical indication: acute severeUC (n=32), steroid-refractory
UC (n=72) and dysplasia/neoplasia (n=22).31 CMV detected by
H&E and IHC staining was more common in those with acute
severe colitis (n=8 with IHC) than in either the refractory UC
group (6 with IHC) or the neoplasia groups (n=0), pb0.03).
This is consistent with more severe inflammation being a
confounding factor, but does not address whether this is cause
or effect for CMV. It is difficult to address in experimental
design, since itwould require a steroid-resistant groupwithout
severe inflammation. Such a group would have relatively
quiescent disease and not require systemic steroids.
4. Conclusions
There is significant heterogeneity in experimental design of
studies on CMV, ulcerative colitis and steroid-resistance.
Distinctions need to be made between colonic mucosal CMV
disease (CMV colitis), identified by standard histopathology
and confirmed by immunohistochemistry; and CMV infection
with antigenaemia quantified by PCR, or positive CMV
serology. There is sufficient evidence to conclude that CMV
disease increases the biological severity of colitis and is
the cause of acute severe colitis in a small minority (around
3–5%), not all of whom are on immunosuppressive therapy.
The diagnostic possibility should be considered at an early
stage, in patients with a high fever, rapid deterioration of
previously stable disease, or no response to intensive therapy
within 3 days. Such patients may be appropriate candidates
for anti-viral therapy, but randomised controlled trials are
needed to identify this cohort and elucidate the response to
anti-viral therapy. There is only circumstantial evidence that
CMV infection detected by viraemia contributes to steroid-
resistance in patients with UC who do not have biologically
severe disease. The possibility that steroids simply cause
self-limiting viral reactivation has to be considered. There is
insufficient evidence that the benefits of anti-viral therapy
in these patients outweigh the risks and no evidence for
chemoprophylaxis against CMV reactivation.
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